BackgroundCheck.run
Search For

Dale L Ludwig, 6214 Lookout Rd, Dover, NJ 07869

Related to:
Donna Ludwig 68 Dwight Ludwig 54 Dwight Ludwig Heidi Ludwig 68 Corin Ludwig 42 Daniel Ludwig 68 Donna Ludwig 88 Dean Ludwig 64 Daniel Ludwig 94

Dale Ludwig Phones & Addresses

14 Lookout Rd, Randolph, NJ 07869    973-3287438   

Blacksburg, VA   

Get Report
Control this profile

Mentions for Dale L Ludwig

Dale Ludwig resumes & CV records

Resumes

Dale Ludwig Photo 38

Chief Scientific Officer

Location:
New York, NY
Industry:
Biotechnology
Work:
Actinium Pharmaceuticals, Inc.
Chief Scientific Officer Eli Lilly and Company Mar 2009 - Dec 2017
Vice President, Research - Biologics Technology Imclone Systems, A Wholly-Owned Subsidiary of Eli Lilly and Company Jan 2005 - Feb 2009
Assistant Vice President and Department Head, Molecular and Cellular Engineering Imclone Systems, A Wholly-Owned Subsidiary of Eli Lilly and Company Jan 2002 - Dec 2004
Associate Director, Department of Molecular and Cellular Biology Imclone Systems, A Wholly-Owned Subsidiary of Eli Lilly and Company Nov 1997 - Dec 2001
Senior Scientist, Department of Molecular and Cellular Biology Los Alamos National Laboratory Jul 1994 - Oct 1997
Postdoctoral Associate, Dna Damage and Repair Group, Life Sciences Division University of Cincinnati Jul 1991 - Jun 1994
Postdoctoral Fellow, Department of Molecular Genetics, Biochemistry, and Microbiology
Education:
East Carolina University 1986 - 1991
Doctorates, Doctor of Philosophy, Microbiology James Madison University 1979 - 1983
Bachelors, Bachelor of Science, Biology
Skills:
Biotechnology, Molecular Biology, Antibody Drug Discovery and Development, Life Sciences, Biochemistry, Pharmaceutical Industry, Drug Discovery, Drug Development
Dale Ludwig Photo 39

Dale Ludwig

Dale Ludwig Photo 40

Dale Ludwig

Dale Ludwig Photo 41

Dale Ludwig

Publications & IP owners

Us Patents

Vdup1 Promoter And Methods Of Use Thereof

US Patent:
6410723, Jun 25, 2002
Filed:
Jul 24, 2000
Appl. No.:
09/625040
Inventors:
Dale Ludwig - Rockaway NJ
Assignee:
Imclone Systems Incorporated - New York NY
International Classification:
C07H 2104
US Classification:
536 241, 536 231, 4353201, 435325
Abstract:
A substantially purified nucleic acid molecule comprising a VDUP1 promoter region, capable of directing expression of a polypeptide encoding sequence to which it is operably linked, whose expression is induced to maximal levels as a result of prolonged cell culture.

Fully Human Antibodies Directed Against The Human Insulin-Like Growth Factor-1 Receptor

US Patent:
7638605, Dec 29, 2009
Filed:
May 3, 2004
Appl. No.:
10/555407
Inventors:
Dale L. Ludwig - Randolph NJ, US
Assignee:
ImClone, LLC - New York NY
International Classification:
C07K 16/00
C12P 21/08
A61K 39/395
C12P 21/04
C12N 5/06
C12N 15/02
US Classification:
53038815, 5303881, 53038822, 5303888, 5303917, 4241411, 4241421, 4241431, 4241551, 4241811, 4241831, 435 696, 435 7021, 435330, 435449
Abstract:
This invention relates to human antibodies that bind to human insulin-like growth factor-1 receptor (IGF-IR), to derivatives of these antibodies (Fabs, single chain antibodies, bi-specific antibodes, or fusion proteins), and to uses of the antibodies and derivatives in therapeutic, and diagnostic methods. The invention relates to nucleic acids encoding the anti-IGF-IR, methods of generating the antibodies and expression. The invention further relates to combination therapies using ant-IGF-IR antibodies with anti-neoplastic drugs.

Fully Human Antibodies Directed Against The Human Insulin-Like Growth Factor-1 Receptor

US Patent:
7968093, Jun 28, 2011
Filed:
Dec 17, 2009
Appl. No.:
12/640671
Inventors:
Dale L Ludwig - Randolph NJ, US
Assignee:
ImClone LLC - New York NY
International Classification:
A61K 39/395
C12P 21/04
C12P 21/08
C12N 5/06
C12N 15/02
C07K 16/00
US Classification:
4241431, 4241411, 4241421, 4241551, 4241811, 4241831, 435 696, 435 7021, 435330, 435449, 5303881, 53038815, 53038822, 5303888, 5303917
Abstract:
This invention relates to human antibodies that bind to human insulin-like growth factor-1 receptor (IGF-IR), to derivatives of these antibodies (Fabs, single chain antibodies, bi-specific antibodies, or fusion proteins), and to uses of the antibodies and derivatives in therapeutic, and diagnostic methods. The invention relates to nucleic acids encoding the anti-IGF-IR, methods of generating the antibodies and expression. The invention further relates to combination therapies using ant-IGF-IR antibodies with anti-neoplastic drugs.

Igf-Ir Antagonists As Adjuvants For Treatment Of Prostate Cancer

US Patent:
7972600, Jul 5, 2011
Filed:
Feb 5, 2007
Appl. No.:
11/702838
Inventors:
Dale L. Ludwig - Randolph NJ, US
Stephen R. Plymate - Des Moines WA, US
Assignee:
ImClone LLC - New York NY
University of Washington - Seattle WA
International Classification:
A61K 39/395
A61K 47/48
A61K 31/517
C07K 16/00
C07K 16/28
US Classification:
4241551, 4241431, 5142662, 51426621, 5303879, 53038822, 544284
Abstract:
The present invention relates to a method of treating prostate cancer with androgen deprivation therapy and an insulin-like growth factor receptor (IGF-IR) antagonist. Although the response rate of prostate cancer to androgen deprivation therapy (ADT) is high, surviving cancer cells invariably become androgen independent (AI) and tumor growth follows. The invention inhibits or delays transition of androgen dependent cancer to androgen independent cancer, significantly decreases risk of recurrence, and improves treatment outcome.

Receptor Antagonists For Treatment Of Metastatic Bone Cancer

US Patent:
2009011, Apr 30, 2009
Filed:
Jun 19, 2006
Appl. No.:
11/917890
Inventors:
Dale L. Ludwig - Randolph NJ, US
Stephen R. Plymate - Des Moines WA, US
Assignee:
ImClone Systems Incorporated - New York NY
University of Washington - Seattle WA
International Classification:
A61K 39/395
A61P 35/00
A61K 31/337
A61K 31/704
C12N 15/13
C12N 15/63
C12N 5/10
C12N 1/19
US Classification:
4241331, 4241301, 4241361, 514449, 514 34, 4241781, 536 2353, 4353201, 435325, 435358, 435365, 4353721, 4352542
Abstract:
The invention provides methods of treating bone cancer, particularly metastatic bone cancer, by administering an IGF-IR antagonist and/or a PDGFRα antagonist. The invention also provides antibodies that bind to human PDGFRα and neutralize activation of the receptor. The invention further provides a methods for neutralizing activation of PDGFRα, and a methods of treating a mammal with a neoplastic disease using the antibodie alone or in combination with other agents.

Compositions And Methods Of Immunodepletion For The Treatment Of Malignant And Non-Malignant Hematological Diseases

US Patent:
2022021, Jul 7, 2022
Filed:
Apr 24, 2020
Appl. No.:
17/606254
Inventors:
- New York NY, US
Dale L. Ludwig - Rockaway NJ, US
Assignee:
ACTINIUM PHARMACEUTICALS, INC. - New York NY
International Classification:
A61K 51/10
C07K 16/28
A61P 35/02
A61K 35/28
Abstract:
This invention provides a method for depleting a subject's hematopoietic stem cells that includes administering to the subject an effective amount of a radiolabeled antibody against CD34, CD117, or CD135, where preferred radiolabels include I and Ac. This invention also provides a method for treating a subject afflicted with a non-cancerous disorder treatable via genetically edited cell therapy, where the method includes (i) administering to the subject an amount of the radiolabeled antibody effective to deplete the subject's hematopoietic stem cells, and (ii) after a suitable time period, performing the therapy on the subject to treat the subject's disorder. Finally, this invention provides articles of manufacture for performing the subject methods.

Molecules And Their Derivatives Directed Aganist Cd45

US Patent:
2020033, Oct 29, 2020
Filed:
Apr 6, 2020
Appl. No.:
16/840806
Inventors:
- New York NY, US
Dale L. LUDWIG - Rockaway NJ, US
Assignee:
Actinium Pharmaceuticals, Inc. - New York NY
International Classification:
A61K 51/10
A61K 35/12
C07K 14/705
Abstract:
The present disclosure provides epitopes of CD45, and binding agents such as antibodies, antibody fragments, peptides, and small molecules capable of binding to those epitopes. The present disclosure also provides methods of treating cancers, hematological diseases and disorders, and immune diseases and disorders, using these binding agents.

Anti-Canine Platelet Derived Growth Factor Receptor Alpha Antibody

US Patent:
2019030, Oct 3, 2019
Filed:
Jul 20, 2017
Appl. No.:
16/318944
Inventors:
- Greenfield IN, US
DALE Lincoln LUDWIG - Rockaway NJ, US
Juqun SHEN - Flushing NY, US
Cheng WANG - Forest Hills NY, US
International Classification:
C07K 16/28
Abstract:
The present disclosure relates to anti-canine platelet derived growth factor receptor alpha antibodies binding to canine platelet derived growth factor receptor alpha.

Possible Relatives

Dean E Ludwig  Daniel E Ludwig  Dated J Ludwig  Diana Ludwig  Donna M Ludwig  Doris D Ludwig  Duane M Ludwig  Dale H Johnston  Dale White  Dale K Jones 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.